Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: a narrative review

• Autori principali: Wei C. Yuet (Autore), Didi Ebert (Autore), Michael Jann (Autore)
• Natura: Libro
• Pubblicazione: SAGE Publishing, 2021-03-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Neurocognitive adverse events have been observed with the widespread use of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors or "statins," which reduce low-density lipoprotein cholesterol (LDL-C) levels and subsequently cardiovascular risk. The United States Food and Drug Association di...